Vaxart, Inc. (VXRT) is a publicly traded company in the Unknown sector. Across all available filings, 22 corporate insiders have executed 214 transactions totaling $328.5M, demonstrating a bearish sentiment with -$322.5M in net insider flow. The most recent transaction on Feb 2, 2026 involved a transaction of 9,265 shares valued at $5.6K.
No significant insider buying has been recorded for VXRT in the recent period.
No significant insider selling has been recorded for VXRT in the recent period.
Based on recent SEC filings, insider sentiment for VXRT is bearish with an Insider Alignment Score of 1/100 and a net flow of -$322.5M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Vaxart, Inc. (VXRT) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 22 insiders are actively trading VXRT stock, having executed 214 transactions in the past 90 days. The most active insider is Steven Boyd (Executive), who has made 38 transactions totaling $298.0M.
Get notified when executives and directors at VXRT file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 2, 2026 | Tucker Sean | SVP, Chief Scientific Officer | Payment | 9,265 | $0.61 | $5.6K | |
| Feb 2, 2026 | B. Berg Edward | SVP, General Counsel | Payment | 9,265 | $0.61 | $5.6K | |
| Feb 2, 2026 | F. Cummings James | Chief Medical Officer | Payment | 7,965 | $0.61 | $4.8K | |
| Dec 4, 2025 | Lo Steven | Executive | Award | 151,351 | $N/A | $0 | |
| Dec 4, 2025 | Lo Steven | Executive | Payment | 54,153 | $0.37 | $20.0K | |
| Nov 17, 2025 | J. Heron Elaine | Executive | Purchase | 16,783 | $0.41 | $6.9K | |
| Nov 17, 2025 | J. Heron Elaine | Executive | Purchase | 23,217 | $0.39 | $9.1K | |
| Nov 17, 2025 | Mark Watson W. | Executive | Purchase | 5,000 | $0.41 | $2.0K | |
| Nov 17, 2025 | Mark Watson W. | Executive | Purchase | 15,000 | $0.41 | $6.2K | |
| Aug 15, 2025 | Finney Kevin | Executive | Purchase | 50,000 | $0.37 | $18.5K | |
| Aug 15, 2025 | Finney Kevin | Executive | Purchase | 50,000 | $0.35 | $17.5K | |
| Jul 30, 2025 | Finney Kevin | Executive | Purchase | 25,874 | $0.38 | $9.8K | |
| Jul 29, 2025 | Mark Watson W. | Executive | Purchase | 10,000 | $0.41 | $4.1K | |
| Jul 28, 2025 | Finney Kevin | Executive | Purchase | 20,000 | $0.40 | $8.0K | |
| Jul 25, 2025 | Finney Kevin | Executive | Purchase | 20,000 | $0.39 | $7.8K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 63 | $325.5M | 96.0% |
Exercise (Options)(X) | 6 | $9.7M | 2.9% |
Purchase(P) | 45 | $3.0M | 0.9% |
Exercise(M) | 24 | $685.2K | 0.2% |
Payment(F) | 16 | $180.8K | 0.1% |
Award(A) | 50 | $0 | 0.0% |
Gift(G) | 8 | $0 | 0.0% |
Other(J) | 2 | $0 | 0.0% |
Insider selling pressure at Vaxart, Inc. has increased, with 22 insiders executing 214 transactions across all time. Total sales of $325.5M significantly outpace purchases of $3.0M, resulting in a net outflow of $322.5M. This selling activity appears largely discretionary, which may warrant closer attention from investors.